Availability of flow cytometric immunophenotyping of lymphocytes to hospital patients--United States, 1990.
The pathogenesis of disease caused by human immunodeficiency virus (HIV) is largely attributable to the decrease in T-lymphocytes bearing the CD4 cell-surface molecule (CD4 + T-lymphocytes) (1). The percentage of CD4 + T-lymphocytes among total lymphocytes and the percentages of other lymphocyte subpopulations (e.g., CD8 + T-lymphocytes) are generally measured by flow cytometric immunophenotyping (FCl) (also called immunophenotyping by flow cytometry [2], T-lymphocyte immunophenotyping [3], and fluorescence-activated cell sorting). FCl results are frequently used to guide the treatment of HIV-infected persons. To assess the availability of FCl to hospital patients, in 1990, the National Public Health and Hospital Institute (NPHHI), a private, nonprofit research institute, surveyed hospitals about their provision of FCl to patients. This report presents findings from the survey.
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood; D015496:CD4-Positive T-Lymphocytes; D002452:Cell Count; D005434:Flow Cytometry; D015658:HIV Infections / Q000097:blood; D006760:Hospitalization; D006801:Humans; D016130:Immunophenotyping / Q000191:economics / Q000706:statistics & numerical data*; D013601:T-Lymphocytes; D014481:United States